2025年5月30日-6月3日，美国临床肿瘤学会（ASCO）年会将于美国伊利诺伊州芝加哥举行。近日，ASCO官网公布了摘要题目及讲者信息。【肿瘤资讯】特别整理了全体大会（Plenary Session）、口头摘要专场（Oral Abstract Session）、口头摘要速递专场（Rapid Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）的中枢神经系统肿瘤领域研究，与读者分享。
口头摘要专场
（Oral Abstract Session）
摘要号：LBA2000
英文标题：Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial.
中文标题：STUPP方案联合或不联合安罗替尼治疗新诊断胶质母细胞瘤的疗效和安全性：一项多中心、双盲、随机II期试验的结果
汇报者：陈媛媛 (中山大学肿瘤防治中心)
摘要号：2001
英文标题：A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: A report by the RANO resect group.
中文标题：IDH突变2级胶质瘤切除范围的预后分层系统：RANO切除组报告
汇报者：Philipp Karschnia (Department of Neurosurgery, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg)
摘要号：2002
英文标题：Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.
中文标题：EORTC随机III期组间CATNON试验关于无1p/19q共缺失的间变性胶质瘤同步和辅助替莫唑胺治疗的最终临床和分子分析：NCT00626990
汇报者：Martin J. Van Den Bent (Erasmus MC Cancer Institute)
摘要号：2003
英文标题：A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.
中文标题：一项佩米替尼治疗经治伴FGFR1-3激活突变胶质母细胞瘤或其他胶质瘤的II期研究：FIGHT-209结果
汇报者：Enrico Franceschi (IRCCS Istituto delle Scienze Neurologiche di Bologna)
摘要号：2004
英文标题：A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.
中文标题：一项asandeutertinib (TY-9591)治疗EGFR阳性突变伴脑转移的晚期NSCLC患者的II期研究
汇报者：石远凯 (中国医学科学院肿瘤医院)
摘要号：2005
英文标题：Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.
中文标题：Patritumab deruxtecan (HER3-DXd)治疗转移性乳腺癌(mBC)和非小细胞肺癌(aNSCLC)的活动性脑转移(BM)以及晚期实体瘤的软脑膜疾病(LMD)：TUXEDO-3 II期试验结果
汇报者：Matthias Preusser (Division of Oncology, Department of Internal Medicine I, Medical University of Vienna)
摘要号：2006
英文标题：A phase II study of an anti-telomerase CD4+ T-helper vaccine (UCPVax) with or without temozolomide in newly diagnosed glioblastoma.
中文标题：一项抗端粒酶CD4+ T辅助细胞疫苗(UCPVax)联合或不联合替莫唑胺治疗新诊断胶质母细胞瘤的II期研究
汇报者：Antoine Carpentier (Hôpital Saint-Louis)
摘要号：2007
英文标题：INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).
中文标题：INB-200：基因修饰的自体γδ T细胞用于接受替莫唑胺(TMZ)维持治疗的新诊断多形性胶质母细胞瘤(GBM)患者的I期研究
汇报者：Louis B. Nabors (Division of Neuro-oncology, Department of Neurology, University of Alabama at Birmingham)
摘要号：2008
英文标题：Immunological correlates from phase I study of CARv3-TEAM-E in patients with recurrent glioblastoma (GBM): INCIPIENT trial.
中文标题：复发性胶质母细胞瘤(GBM)患者接受CARv3-TEAM-E治疗的I期研究的免疫学相关性分析：INCIPIENT试验
汇报者：Bryan D. Choi (Massachusetts General Hospital)
口头摘要速递专场
（Rapid Oral Abstract Session）
摘要号：2012
英文标题：Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis: A prospective, single-arm, phase II trial.
中文标题：优替德隆联合依托泊苷和贝伐珠单抗治疗脑转移的HER2阴性乳腺癌症患者：一项前瞻性、单臂、II期试验
汇报者：史业辉 (天津医科大学肿瘤医院)
摘要号：2013
英文标题：Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma.
中文标题：一种突变型IDH1/IDH2(mIDH1/2)抑制剂HMPL-306用于治疗包括胶质瘤在内的晚期mIDH实体瘤西方患者的I期研究
汇报者：Jordi Rodon Ahnert (The University of Texas MD Anderson Cancer Center)
摘要号：2015
英文标题：Results from phase 1 study of mycophenolate mofetil with chemoradiation in newly diagnosed glioblastoma to target de-novo purine metabolism to overcome treatment resistance.
中文标题：麦考酚酯与放化疗联合治疗新诊断胶质母细胞瘤以靶向从头嘌呤代谢进而克服治疗抵抗的I期研究结果
汇报者：Yoshie Umemura (Ivy Brain Tumor Center at Barrow Neurological Institute)
摘要号：2016
英文标题：Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
中文标题：通过拮抗C/EBPβ依赖性间充质细胞转化和免疫抑制性M2巨噬细胞极化在胶质母细胞瘤患者中使用lucicebtide (ST101)
汇报者：Fabio Massaiti Iwamoto (Columbia University Irving Medical Center)
摘要号：2017
英文标题：Safety and tolerability of intraventricular CARv3-TEAM-E T cells following lymphodepleting chemotherapy in recurrent glioblastoma: INCIPIENT trial.
中文标题：复发性胶质母细胞瘤患者淋巴细胞清除化疗后应用脑室内CARv3-TEAM-E T细胞治疗的安全性和耐受性：INCIPIENT试验
汇报者：Elizabeth R. Gerstner (Massachusetts General Hospital)
摘要号：2018
英文标题：A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.
中文标题：B7H3 CAR-T细胞颅内给药治疗复发性胶质母细胞瘤的I期研究
汇报者：Reena Parada Thomas (Stanford University)
摘要号：2019
英文标题：Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
中文标题：Tirabrutinib治疗复发或难治性原发性中枢神经系统淋巴瘤：II期PROSPECT研究的疗效和安全性结果
汇报者：Lakshmi Nayak (Dana-Farber Cancer Institute)
摘要号：2020
英文标题：Using single-cell transcriptomics to reveal CD226 upregulation and enhancement of CD19-CAR-T function in the inhibitory CNS microenvironment of refractory CNS lymphoma.
中文标题：利用单细胞转录组学揭示难治性中枢神经系统淋巴瘤抑制性微环境中CD226的上调及CD19-CAR-T功能的增强
汇报者：Ulrike Gerdemann (Dana-Farber/Boston Children's Cancer and Blood Disorders Center)
临床科学研讨会
（Clinical Science Symposium）
摘要号：2009
英文标题：Multicenter trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) with monthly adjuvant temozolomide for patients with high-grade gliomas.
中文标题：微泡增强经颅聚焦超声（MB-FUS）联合每月替莫唑胺辅助治疗高级别胶质瘤患者的多中心试验
汇报者：Graeme Woodworth (University of Maryland School of Medicine)
摘要号：2010
英文标题：Leveraging stimulated Raman histology-based cellularity for random forest prediction of glioblastoma recurrence.
中文标题：利用基于受激拉曼组织学的细胞密度进行随机森林预测胶质母细胞瘤复发
汇报者：Sanjeev Herr (Drexel University College of Medicine)
摘要号：2011
英文标题：Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.
中文标题：立体定向放疗对比海马回避全脑放疗治疗在伴5-20个脑转移灶的患者中的应用：一项多中心、III期随机试验
汇报者：Ayal Aizer (Brigham and Women's Hospital/Dana-Farber Cancer Institute)
*本文根据目前官网信息整理汇总，如有疏漏，欢迎补充指正。
排版编辑：肿瘤资讯-丹忱
苏公网安备32059002004080号
